Who founded Hemostemix?

Hemostemix was founded by Roger Bergersen, Thomas A. Smeenk in 2014.

Who are Hemostemix's investors?

Hemostemix's investors include BioBrit.

Where is Hemostemix headquartered?

Hemostemix is headquartered in Blackfalds.

Hemostemix

Blackfalds · Founded 2014 · 11 employees on LinkedIn · 1 known investors

Find your way into Hemostemix

203 people in our graph share verified history with the Hemostemix team — schools, employers, funds. One of them is your warm intro.

Mariam Kamelunlockedknows Thomas A. Smeenk · together at Western University (overlapped)

knows the team · via Western University

×5knows the team · via Xerox Canada

×5knows the team · via Carleton University

Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).

Biotech Healthtech Longevity Medical Devices

Founders & leadership

Hemostemix was founded in 2014 by Roger Bergersen and Thomas A. Smeenk.

Roger BergersenFounder (of predecessor TheraVitae Inc.)

Thomas A. Smeenk inPresident & CEO, Co-FounderThomas A. Smeenk is President and CEO of Hemostemix, a publicly traded regenerative medicine company developing ACP-01, an autologous stem cell therapy for ischemic and vascular diseases. He co-founded the company and has led its clinical development and regulatory strategy over multiple decades.

Ina SarelinVice President R&D2011–2017

Kyle Makofka inCEO2016–2019President & CEO at Ardenton Capital Corporation

David BermanChief Financial Officer

Dr. Fraser HendersonChief Medical Officer

Angus JenkinsNamed on SEC filing

Don FriesenNamed on SEC filing

David L. WoodNamed on SEC filing

Investors · 1

BioBritLa Jolla

Reported raises · per SEC filings

Form D private placements

▶$132.1KofferedSep 2017 · 2 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Angus JenkinsDirector
Don FriesenDirector
Ina SarelExecutive Officer
Kyle MakofkaExecutive Officer
David BermanExecutive Officer
David L. WoodDirector

Offering amount: $132.1K
First sale: Aug 2017
Incorporated: Corporation, Alberta, Canada, 2014
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

American Endovascular12 shared keywordsOutpatient centers for treatment of peripheral artery disease.

Osmosis10 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.

Companies competing with Hemostemix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Hemostemix do?: Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).
Who founded Hemostemix?: Hemostemix was founded by Roger Bergersen, Thomas A. Smeenk in 2014.
Who are Hemostemix's investors?: Hemostemix's investors include BioBrit.
Where is Hemostemix headquartered?: Hemostemix is headquartered in Blackfalds.